Psychological and Cognitive-Emotional Symptoms
1 Anxiety
Clinical Presentation.
- Generalized anxiety
- Panic attacks
- Health anxiety (realistic concern about worsening condition)
- Anticipatory anxiety about exertion, crashes, or medical appointments
- Hypervigilance about energy levels and symptom changes
Distinction from Primary Anxiety Disorder. Anxiety in ME/CFS is typically secondary—a realistic response to living with a disabling, unpredictable illness. The anxiety often improves if symptoms improve, unlike primary anxiety disorders.
2 Depression
Clinical Presentation.
- Low mood and sadness
- Anhedonia (inability to experience pleasure)
- Hopelessness about future
- Suicidal ideation (in severe cases)
- Grief over lost capabilities and identity
Reactive vs. Primary Depression. The majority of ME/CFS patients who experience depression develop it after disease onset (78.1%), and 96% attribute it to disease severity rather than pre-existing psychiatric conditions. Depression in ME/CFS is typically reactive: a normal emotional response to severe, chronic illness and loss of function.
Distinguishing Features.
- Depression correlates with disease severity and functional impairment
- Desire to be active is present, but physical capacity is absent
- Effort expenditure is maximal despite minimal output (opposite of primary depression)
- Depression often improves if physical symptoms improve
A large single-cell molecular atlas of the adult human hippocampus (\(n \approx 500{,}000\) nuclei) reported that neurogenesis — the birth of new neurons in the dentate gyrus — is stalled in major depressive disorder: more quiescent neural stem cells, fewer maturing neuroblasts, and reduced BDNF and DCX, alongside elevated interferon and cellular-stress signaling across the hippocampal trisynaptic circuit (Peng et al. 2026). The authors frame this as a molecular basis for reclassifying depression by its cellular features, analogous to how cancer is subclassified by molecular characteristics rather than location (Peng et al. 2026).
The question for ME/CFS is whether this molecular signature distinguishes primary major depression from the reactive low mood that most ME/CFS patients develop after disease onset. The reactive hypothesis holds that ME/CFS-associated low mood is an emotional response to chronic illness (see above), and would predict no primary hippocampal neurogenesis defect in most ME/CFS patients. The alternative — that a shared post-infectious or HPA-axis process suppresses hippocampal neurogenesis in both conditions — remains speculative: there are currently zero direct studies of adult hippocampal neurogenesis in ME/CFS.
Whether adult human hippocampal neurogenesis occurs at meaningful levels at all remains contested, with conflicting post-mortem evidence (Sorrells et al. 2018) (Sorrells et al. 2021) vs. (Boldrini et al. 2018) (Boldrini et al. 2019) (Eriksson et al. 1998). (Certainty: 0.80 for the MDD finding; the ME/CFS extrapolation is a speculation below 0.45 given the absence of direct ME/CFS data.) (Severity applicability: unknown — the study cohort was depression/MDD, not stratified by ME/CFS severity.)
Consequence: If hippocampal neurogenesis distinguishes molecular depression from reactive low mood, it could one day help clinicians separate primary depressive disorder from the demoralization that accompanies severe chronic illness — but this requires direct ME/CFS studies that do not yet exist, and the field still disputes whether the underlying process is measureable in adults at all.
Because adult hippocampal neurogenesis cannot currently be measured in living patients (post-mortem only, and the field is divided on whether it is measureable in adults at all (Sorrells et al. 2018) vs. (Boldrini et al. 2018)), pattern separation — the dentate-gyrus-dependent ability to discriminate overlapping memories — is proposed as a behavioural proxy that could separate primary molecular depression from reactive low mood without tissue. Pattern separation is impaired in major depressive disorder and has been proposed as a neurogenesis-linked behavioural marker (Gandy et al. 2017). (Certainty: 0.40 — an indirect, cross-disease inference; the behavioural marker is established in MDD, but its ME/CFS application is untested.) (Origin: brainstorm.) (Severity applicability: unknown — not stratified by ME/CFS severity.)
Falsifiability: In a ME/CFS cohort stratified by depression onset, patients with post-onset reactive low mood should perform normally on a mnemonic-similarity pattern-separation task, whereas the small expected subgroup with primary depression-like presentations should show selective pattern-separation impairment correlating with anhedonia rather than with fatigue or post-exertional malaise; the dissociation would be falsified if pattern-separation performance tracks fatigue/PEM instead of depression subtype.
Consequence: If a simple memory task reliably separated “depression as a reaction to illness” from “depression as a brain change,” it would give clinicians a non-invasive way to decide whether the two need different management — but it is a research hypothesis, not yet a clinical test. For the convergent cross-disease argument, see The Molecular Depression–ME/CFS Boundary: A Convergent, Speculative Thread.
3 Emotional Lability and Mood Dysregulation
Clinical Presentation.
- Easy crying or emotional overwhelm
- Irritability and low frustration tolerance
- Rapid mood shifts
- Difficulty regulating emotional responses
- Emotional symptoms worsening with fatigue
Mechanism. Emotional regulation requires prefrontal cortex function and adequate neurotransmitter availability. Energy deficit impairs executive control over emotions, leading to lability.